Invasive ductal carcinoma and small lymphocytic lymphoma/chronic lymphocytic leukemia manifesting as a collision breast tumor: A case report and literature review.

SLL/CLL breast carcinoma collision tumor invasive ductal carcinoma lymphoma

Journal

Open life sciences
ISSN: 2391-5412
Titre abrégé: Open Life Sci
Pays: Poland
ID NLM: 101669614

Informations de publication

Date de publication:
2021
Historique:
received: 18 05 2021
revised: 11 07 2021
accepted: 21 07 2021
entrez: 15 9 2021
pubmed: 16 9 2021
medline: 16 9 2021
Statut: epublish

Résumé

Collision breast tumors, consisting of breast cancer (BC) and non-Hodgkin's lymphoma (NHL), are extremely rare. Here we report the case of a 64-year-old woman with a collision tumor in her left breast mass that was composed of invasive ductal carcinoma and small lymphocytic lymphoma/chronic lymphocytic leukemia. In addition, we reviewed the published comparable English-language literature. Collision breast tumor composed of BC and NHL is extremely rare. For that reason, there is a lack of consensus about the underlying mechanism, and diagnosing it without delay remains a complex clinical challenge. We found that post-menopausal, age-related estrogen levels changes and Epstein-Barr virus infection are possible pathogenic factors. However, the symptoms are almost identical, and it is difficult to distinguish a simple breast tumor from a breast collision tumor. In this study, we reviewed the clinical features of all patients with BC and NHL colliding breast tumors; this information might enable early identification and prevention of misdiagnosis.

Identifiants

pubmed: 34522780
doi: 10.1515/biol-2021-0093
pii: biol-2021-0093
pmc: PMC8402943
doi:

Types de publication

Case Reports

Langues

eng

Pagination

867-871

Informations de copyright

© 2021 Xiaowen Chen et al., published by De Gruyter.

Déclaration de conflit d'intérêts

Conflict of interest: The authors state no conflict of interest.

Références

Breast J. 2007 Jul-Aug;13(4):413-7
pubmed: 17593048
Medicine (Baltimore). 2019 Sep;98(39):e17043
pubmed: 31574801
Exp Ther Med. 2020 Oct;20(4):3458-3461
pubmed: 32905114
Arch Pathol Lab Med. 2004 Jan;128(1):99-101
pubmed: 14692838
Anticancer Res. 2021 Jul;41(7):3639-3642
pubmed: 34230161
Indian J Med Paediatr Oncol. 2016 Jul-Sep;37(3):146-51
pubmed: 27688607
PLoS One. 2012;7(11):e48788
pubmed: 23183846
Front Oncol. 2017 May 26;7:110
pubmed: 28603694
J Surg Case Rep. 2016 Jan 22;2016(1):
pubmed: 26801778
J Labelled Comp Radiopharm. 2019 Oct;62(12):850-859
pubmed: 31461549
Leuk Lymphoma. 2013 Apr;54(4):720-5
pubmed: 22916741
Maturitas. 2011 Feb;68(2):129-36
pubmed: 21145188
Int J Surg Pathol. 2018 Jun;26(4):296-305
pubmed: 29320898
Clin Nucl Med. 2021 Apr 1;46(4):e214-e215
pubmed: 33208615
EBioMedicine. 2016 Jul;9:148-160
pubmed: 27333046
South Med J. 2006 Feb;99(2):164-7
pubmed: 16509555
J Mammary Gland Biol Neoplasia. 2013 Mar;18(1):25-42
pubmed: 23392570
Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1747-55
pubmed: 23885038
Clin Breast Cancer. 2015 Aug;15(4):e209-12
pubmed: 25818398
Cureus. 2020 Aug 28;12(8):e10104
pubmed: 33005523

Auteurs

Xiaowen Chen (X)

Department of Oncology Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.

Jianli Chen (J)

The Third Department of Medical Oncology, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.

Sihai Liao (S)

Department of Oncology Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.

Yuwen Cao (Y)

Department of Pathology, Shihezi University School of Medicine, Shihezi, Xinjiang, China.

Classifications MeSH